New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

F. Hoffmann-La Roche Ltd

Contributing Author

Recent Articles by F. Hoffmann-La Roche Ltd

May-31	New data show Roche's Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer ROG GlobeNewswire
May-30	Roche's fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis ROG GlobeNewswire
May-23	CHMP recommends EU approval of Roche's Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer ROG GlobeNewswire
May-23	Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology ROG GlobeNewswire
May-23	New two-year follow-up of Roche's Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients ROG GlobeNewswire
May-22	FDA approves Roche's Susvimo for diabetic retinopathy ROG GlobeNewswire
May-20	Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma ROG GlobeNewswire
May-14	Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis ROG GlobeNewswire
May-13	Ten-year APHINITY data show Roche's Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer ROG GlobeNewswire
May-06	Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity ROG GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.